B+
Bull case
15%
Probability
Target price
$26.88
Analysis reference price unavailable
Analysis 2026-03-07 · RankAlpha Sentiment AI
TNGX
Tango TherapeuticsFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment AIMost likely
B
Base case
55%
Probability
Target price
$15.50
Analysis reference price unavailable
Analysis 2026-03-07 · RankAlpha Sentiment AI
B-
Bear case
30%
Probability
Target price
$10.10
Analysis reference price unavailable
Analysis 2026-03-07 · RankAlpha Sentiment AI
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-03-07
Recent news sentiment (30D)
-
Unavailable
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+21.7
Score
AI commentary
Sentiment is mixed: analyst targets cluster in the mid‑teens while a subset of higher outliers creates dispersion and episodic volatility [#SERP-3]. The analyst median sits below the current anchor, implying limited near‑term upside absent positive trial or partnership news [#SERP-1]. Overall tone is cautious; the stock remains highly sensitive to binary clinical and funding catalysts [#SERP-5].
RankAlpha Sentiment AI - 2026-03-07
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-06-05eventPartnership, licensing, or M&A interestHigh impact
Potential partnership or acquisition interest could surface within months; no public window disclosed, assumed conservative near-term window end for modeling purposes (assumption noted) [#SERP-3].
2026-06-05catalystNear-term analyst target revisions and sentimentHigh impact
Recent analyst activity and target updates (e.g., MarketBeat note and consensus pages) may drive price re-rating over the next quarter; watch for further target updates and notes that could lower consensus toward the median [#SERP-3], [#SERP-1].
2027-03-07catalystPipeline clinical-data readouts or milestone updatesHigh impact
Positive late-stage or exploratory trial readouts and milestone progress would materially re-rate value over a longer horizon; absence or negative outcomes would amplify downside risk (biotech binary) [#SERP-5].
Recommendation
N/A
No formal recommendation provided.
As of 2026-03-07 • Updated nightlySource: Internal modelMethodology